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ABSTRACT
There is evidence from clinical case reports and epidemiological studies that human immunodeficiency
virus (HIV) can be transmitted through oral sex. Herpes viruses that appear in the oral mucosa might
influence the oral replication of HIV. A review of data suggesting that interactions occur between HIV
and herpes viruses indicates that such interactions might operate in the oral mucosa. Defining the
mechanisms by which herpes viruses interact with HIV in the oral mucosa should permit intervention
measures to be targeted more precisely.
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There is growing evidence that human immuno-
deficiency virus (HIV) can be transmitted through
oral sex. HIV-1 RNA may be present in up to 90%
of whole saliva samples and in 50% of gingival
crevicular fluid samples [1]. Although the virus
burden of saliva is usually less than that of
plasma and semen, it has been reported that HIV
RNA levels in saliva in some patients may be up
to five-fold higher than in plasma [2]. Although
many other viruses can also be found in the oral
mucosa, herpes viruses have been identified in a
wide range of HIV-related oral lesions, e.g.,
herpes simplex virus (HSV) in periodontal disease
[3], cytomegalovirus (CMV) in aphthous-like
ulceration [4], and human herpes virus 8 (HHV-8)
in Kaposi’s sarcoma [5]. It is possible that asymp-
tomatic carriage of herpes viruses may signifi-
cantly influence the oral carriage of HIV (and vice
versa) [6]. Importantly, such viruses have also
been identified in HIV-infected individuals free of
oral disease, e.g., Epstein–Barr virus (EBV) [7] and
HHV-8 [8]. These viruses possess a variety of
mechanisms that might heighten the local car-
riage of HIV.
There is extensive evidence that HSV-1 reacti-
vation in the female genital tract may increase
during HIV replication in co-infected individuals
[9]. The HIV-1 long terminal repeat (LTR) can be
transactivated by HSV-1 immediate–early (IE)
gene products. The ICP0 and ICP4 proteins are
thought to be important mediators of this process,
which is known to involve induction of the
cellular activators NFjB and Sp1 [10]. It is
conceivable that recurrent repeated episodes of
HSV-1 reactivation might directly and regularly
increase the HIV load in oral fluid. HIV-1 virions
have been observed to infect keratinocytes of
HSV-1, which, because they lack the CD4 mole-
cule, are normally incapable of being infected by
HIV-1 [11].
CMV can drive HIV production via heterolo-
gous transactivation by CMV IE gene products of
the HIV-1 LTR, as might occur in cells co-infected
by both HIV and CMV, or cells sharing the same
internal milieu [12]. In particular, CMV encodes
IE2-86, a DNA-binding protein that acts as a
promiscuous transactivator of many virus and
cellular promoters [13], and also IE1-72, which
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stimulates transcription from a CMV promoter, as
well as heterologous viral and cellular promoters
(thereby upregulating NFjB) that play essential
roles in virus life cycles and orchestrate virus-
dependent cytokine expression [14]. To effect
transactivation, CMV IE products may or may
not synergise with the HIV Tat protein, an
important transcriptional transactivator of the
LTR [15].
The oral mucosa, particularly the tongue, is the
site at which EBV undergoes lytic replication.
EBV vegetative replication occurs in the tongue
during the early stages of HIV disease, well before
oral hairy leukoplakia becomes clinically appar-
ent [16]. Infection of primary CD4+ and CD8+
T-lymphocytes by EBV has been shown to
enhance HIV-1 expression [17]. In addition, it
has been shown that, following HIV-1 infection of
CD4+ ⁄CR2+ cell lines transformed by EBV, the
cells showed evidence of HIV-1 upregulation [18];
additional evidence was also provided that the
EBV protein EBNA-2 is required by Tat to
transactivate the HIV-1 LTR [18]. Lytic EBV
infection of B-cells can be associated with super-
antigen-like expression in these cells, leading to
the expansion of Vb12 T-cell receptor-bearing
CD4+ T-cells [19]. Such an expansion potentially
provides a pool of cells susceptible to HIV
infection.
HHV-6 can upregulate the production of CD4
in T-lymphocytes [20]. Increased expression of
CD4 can also be induced by HHV-6 in c ⁄ d T-cells,
a subset of T-cells involved in the protective
immune response against specific microorgan-
isms, rendering them susceptible to HIV-1 infec-
tion [21]. Furthermore, HHV-6 and HIV-1 can
co-infect human CD4+ T-cells, thereby leading to
accelerated cell death, and factors in HHV-
6-infected cells stimulate HIV-1 LTR-directed
gene expression, mediated by HHV-6-induced
nuclear protein(s) that specifically bind to the
NFjB motifs of the HIV-1 enhancer region [22].
However, HHV-6 also appears to be able to
downregulate the HIV-1 co-receptor CXCR4 [23].
How these apparently disparate HHV-6-associ-
ated influences relate to HIV activation in vivo has
not yet been comprehensively studied. Neverthe-
less, there is evidence that the overall influence of
HHV-6 is to increase the systemic HIV-1 viral
load [24]. In contrast, HHV-7 appears to exert
effects on HIV that oppose the effects of HHV-6.
HHV-7 downregulates CD4 expression in
T-lymphocytes [25] and interferes with HIV-1
interaction with CD4 in terminally differentiated
monocytes [26].
The mouth is a major site of HHV-8 carriage [5].
Among HHV-8-seropositive ⁄HIV-1-seronegative
male homosexuals in the USA without Karposi’s
sarcoma [27], HHV-8 DNA was detected in 30%
of oropharyngeal samples, compared with 1% of
anal and genital samples, with the HHV-8 titre
from the oral cavity being up to 2.5-fold higher
than those from other sites; in-situ hybridisation
studies indicated that HHV-8 DNA and mRNA
can be found in oral epithelial cells [27]. HHV-8
encodes chemokine-like proteins (vMIP-I and
vMIP-II) that may interact with HIV-1. vMIP-II
has been shown to block HIV-1 infection in a
CD4+ cell line expressing CCR3 and, to a lesser
extent, in a cell line expressing CCR5, and both
vMIP-I and vMIP-II partially inhibited HIV
infection of peripheral blood mononuclear cells
[28]. Such results would imply that HHV-8 exerts
an anti-HIV-1 effect. However, other studies
suggest otherwise. Thus, the HHV-8 latency-
associated nuclear antigen (LANA), some other
HHV-8-encoded proteins from open reading
frames 50 and 57, and the KIE2 immediate–early
gene product, are able to interact with the HIV
transactivator protein to transactivate the HIV-1
LTR [29].
In conclusion, herpes viruses that appear in the
oral cavity appear to be able to influence oral HIV
replication. The clinical, and certainly the virolo-
gical, influences of herpes virus carriage on the
infectivity of HIV in the mouth have not yet been
fully addressed. There is no published research
on the impact of asymptomatic herpes virus
carriage on the HIV load in the different com-
partments of the mouth, despite substantial
in-vitro evidence to suggest that herpes viruses
have the potential to enhance HIV carriage in the
mouth, and perhaps vice versa. Defining the
mechanisms by which herpes viruses interact
with HIV in the oral mucosa should permit
intervention measures to be targeted more pre-
cisely.
REFERENCES
1. Shugars DC, Wahl SM. The role of the oral environment in
HIV-1 transmission. JADA 1998; 129: 851–858.
2. Liuzzi G, Chirianni A, Clementi M et al. Analysis of HIV-1
load in blood, semen and saliva: evidence for different
84 Clinical Microbiology and Infection, Volume 11 Number 2, February 2005
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 83–85
viral compartments in cross-sectional and longitudinal
study. AIDS 1996; 10: F51–F56.
3. Mardirossian A, Contreras A, Navazesh M, Nowzari H,
Slots J. Herpesviruses 6, 7 and 8 in HIV- and non-HIV-
associated periodontitis. J Periodontol Res 2000; 35: 278–284.
4. Jones AC, Gulley ML, Freedman PD. Necrotizing ulcera-
tive stomatitis in human immunodeficiency virus-sero-
positive individuals: a review of the histopathologic,
immunohistochemical and virologic characteristics of
18 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod
2000; 89: 323–332.
5. Leao JC, Porter S, Scully C. Human herpesvirus 8 and oral
health care: an update. Oral Surg Oral Med Oral Pathol Oral
Radiol Endod 2000; 90: 694–704.
6. Mbopi-Keou FX, Legoff J, Gresenguet G et al. Genital
shedding of HSV-2 DNA and HIV-1 RNA and proviral
DNA in HIV-1- and HSV-2-coinfected African women.
J AIDS 2003; 33: 121–124.
7. Scully C, Porter SR, Di Alberti L, Jalal H, Maitland NJ.
Detection of Epstein–Barr virus in oral scrapes in HIV
infection, in oral hairy leukoplakia and in healthy non-
HIV-infected persons. J Oral Pathol Med 1998; 27: 480–482.
8. Cook RD, Hodgson TA, Waugh AC et al. Mixed patterns
of transmission of human herpesvirus-8 (Kaposi’s sar-
coma-associated herpesvirus) in Malawian families. J Gen
Virol 2002; 83: 1613–1619.
9. Mosca JD, Bednarik DP, Raj NB et al. Herpes simplex virus
type-1 can reactivate transcription of latent human
immunodeficiency virus. Nature 1987; 325: 67–70.
10. Margolis DM, Rabson AB, Straus SE, Ostrove JM. Trans-
activation of the HIV-1 LTR by HSV-1 immediate-early
genes. Virology 1992; 186: 788–791.
11. Heng MC, Heng SY, Allen SG. Co-infection and synergy of
human immunodeficiency virus-1 and herpes simplex
virus-1. Lancet 1994; 343: 225–228.
12. Ghazal P, Young J, Giulietti E et al. A discrete cis element in
the human immunodeficiency virus long terminal repeat
mediates synergistic transactivation by cytomegalovirus
immediate-early proteins. J Virol 1991; 65: 6735–6742.
13. Yurochko AD, Huong SM, Huang ES. Identification of
human cytomegalovirus target sequences in the human
immunodeficiency virus long terminal repeat. Potential
role of IE2-86 binding to sequences between )120 and )20
in promoter transactivation. J Human Virol 1999; 2: 81–90.
14. Yurochko AD, Kowalik TF, Huong SM, Huang ES. Human
cytomegalovirus upregulates NF-kappa B activity by
transactivating the NF-kappa B p105 ⁄p50 and p65 pro-
moters. J Virol 1995; 69: 5391–5400.
15. Dal Monte P, Landini MP, Sinclair J, Virelizier JL,
Michelson S. TAR and Sp1-independent transactivation of
HIV long terminal repeat by the Tat protein in the pres-
ence of human cytomegalovirus IE1 ⁄ IE2. AIDS 1997; 11:
297–303.
16. Boulter AW, Soltanpoor N, Swan AV, Birnbaum W,
Johnson NW, Teo CG. Risk factors associated with
Epstein–Barr virus replication in oral epithelial cells of
HIV-infected individuals. AIDS 1996; 10: 935–940.
17. Guan M, Zhang RD, Wu B, Henderson EE. Infection of
primary CD4+ and CD8+ lymphocytes by Epstein–Barr
virus enhances human immunodeficiency virus expres-
sion. J Virol 1996; 70: 7341–7346.
18. Zhang RD, Guan M, Park Y et al. Synergy between human
immunodeficiency virus type 1 and Epstein–Barr virus in
T lymphoblastoid cell lines. AIDS Res Hum Retroviruses
1997; 13: 161–171.
19. Sutkowski N, Palkama T, Ciurli C, Sekaly RP, Thorley-
Lawson DA, Huber BT. An Epstein–Barr virus-associated
superantigen. J Exp Med 1996; 184: 971–980.
20. Lusso P, De Maria A, Malnati M et al. Induction of CD4
and susceptibility to HIV-1 infection in human CD8+ T
lymphocytes by human herpesvirus 6. Nature 1991; 349:
533–535.
21. Lusso P, Garzino-Demo A, Crowley RW, Malnati MS.
Infection of c ⁄ d T lymphocytes by human herpesvirus 6:
transcriptional induction of CD4 and susceptibility to HIV
infection. J Exp Med 1995; 181: 1303–1310.
22. Ensoli B, Lusso P, Schacther F et al. Human herpesvirus 6
increases HIV-1 expression in co-infected T cells via nuc-
lear factors binding to the HIV-1 enhancer. EMBO J 1989;
8: 3019–3027.
23. Yasukawa M, Hasegawa A, Sakai I et al. Down-regulation
of CXCR4 by human herpesvirus 6 (HHV-6) and HHV-7.
J Immunol 1999; 162: 5417–5422.
24. Emery VC, Atkins MC, Bowen EF et al. Interactions
between beta-herpesviruses and human immunodefi-
ciency virus in vivo: evidence for increased human
immunodeficiency viral load in the presence of human
herpesvirus 6. J Med Virol 1999; 57: 278–282.
25. Lusso P, Secchiero P, Crowley RW, Garzino-Demo A,
Berneman ZN, Gallo RC. CD4 is a critical component of
the receptor for human herpesvirus 7: interference with
human immunodeficiency virus. Proc Natl Acad Sci USA
1994; 91: 3872–3876.
26. Crowley RW, Secchiero P, Zella D, Cara A, Gallo RC,
Lusso P. Interference between human herpesvirus 7 and
HIV-1 in mononuclear phagocytes. J Immunol 1996; 156:
2004–2008.
27. Pauk J, Huang ML, Brodie SJ et al. Mucosal shedding of
human herpesvirus 8 in men. N Engl J Med 2000; 343: 1369–
1377.
28. Boshoff C, Endo Y, Collins PD et al. Angiogenic and HIV-
inhibitory function of KSHV-encoded chemokines. Science
1997; 278: 290–294.
29. Hyun TS, Subramanian C, Cotter MA, Thomas RA,
Robertson ES. Latency-associated nuclear antigen encoded
by Kaposi’s sarcoma-associated herpesvirus interacts with
Tat and activates the long terminal repeat of human
immunodeficiency virus type 1 in human cells. J Virol
2001; 75: 8761–8771.
Mbopi-Keou et al. HIV and herpes viruses in oral mucosa 85
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 83–85
